Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

Johann K. Hitzler, Todd A. Alonzo, Robert Gerbing, Jim Wang, Amy Beckman, Betsy Hirsch, Susana C. Raimondi, Karen M Chisholm, Shelton A. Viola, Anupam Verma, Lisa Eidenschink Brodersen, Michael R. Loken, Jeffrey W. Taub, Alan S Gamis, E. Anders Kolb, Todd M Cooper, Jason N. Berman

Blood (2024) 144 (Supplement 1): 2949.

https://doi.org/10.1182/blood-2024-202621

Published: 2024

Journal Articles

A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO - a Report from the Children's Oncology Group

Blood (2024) 144 (Supplement 1): 967.

https://doi.org/10.1182/blood-2024-205666

Published: 2024

Journal Articles

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Blood (2021) 138 (23): 2337–2346.

https://doi.org/10.1182/blood.2021012206

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group

Blood (2018) 132 (15): 1584–1592.

https://doi.org/10.1182/blood-2018-05-849059

Published: 2018

Includes: Supplemental data

Journal Articles

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Jeffrey W. Taub, Jason N. Berman, Johann K. Hitzler, April D. Sorrell, Norman J. Lacayo, Kelley Mast, David Head, Susana Raimondi, Betsy Hirsch, Yubin Ge, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Dario Campana, Elaine Coustan-Smith, Prasad Mathew, Alan S. Gamis

Blood (2017) 129 (25): 3304–3313.

https://doi.org/10.1182/blood-2017-01-764324

Published: 2017

Includes: Supplemental data

Journal Articles

Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children’s Oncology Group report

Marijana Vujkovic, Edward F. Attiyeh, Rhonda E. Ries, Elizabeth K. Goodman, Yang Ding, Marko Kavcic, Todd A. Alonzo, Yi-Cheng Wang, Robert B. Gerbing, Lillian Sung, Betsy Hirsch, Susana Raimondi, Alan S. Gamis, Soheil Meshinchi, Richard Aplenc

Blood (2017) 129 (23): 3051–3058.

https://doi.org/10.1182/blood-2017-03-772384

Published: 2017

Includes: Supplemental data

Journal Articles

Family History Of Hematologic Malignancies and Disorders In a Population Based Study Of Myelodysplastic Syndromes (MDS)

Angela R. Smith, MD, MS, Erica D. Warlick, MD, Rachel K. Fonstad, M.S., Michelle A. Roesler, Jenny N. Poynter, PhD, Betsy Hirsch, PhD, Phuong L. Nguyen, MD, Adina Cioc, MD, Julie A Ross, PhD

Blood (2013) 122 (21): 1541.

https://doi.org/10.1182/blood.V122.21.1541.1541

Published: 2013

Journal Articles

Disease Characteristics and Prognostic Implications Of Cell Surface FLT3 Receptor (CD135) Expression In Pediatric Acute Myeloid Leukemia – A Report From Children’s Oncology Group

Katherine Tarlock, MD, Todd A. Alonzo, PhD, Michael R. Loken, PhD, Robert B. Gerbing, MA, Richard Aplenc, MD, PhD, Lillian Sung, MD, PhD, Susana C. Raimondi, PhD, Betsy Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 2609.

https://doi.org/10.1182/blood.V122.21.2609.2609

Published: 2013

Journal Articles

Differences In Community and Academic Practice Patterns For Newly Diagnosed Myelodysplastic Syndromes (MDS) Patients In Minnesota: A Population Based Study

Daniel Pease, MD, Julie A Ross, PhD, Phuong L. Nguyen, MD, Betsy Hirsch, PhD, Adina Cioc, MD, Angela R. Smith, MD, MS, Michelle A. Roesler, Rachel K. Fonstad, M.S., Erica D. Warlick, MD

Blood (2013) 122 (21): 2798.

https://doi.org/10.1182/blood.V122.21.2798.2798

Published: 2013

Journal Articles

Discordant World Health Organization (WHO) Classifications In a Population-Based Study Of Adult Myelodysplastic Syndromes (MDS)

Erica D. Warlick, MD, Phuong L. Nguyen, MD, Rachel K. Fonstad, M.S., Adina Cioc, MD, Betsy Hirsch, PhD, Jeffrey S. Miller, MD, Daniel J. Weisdorf, MD, Michelle A. Roesler, Julie A Ross, PhD

Blood (2013) 122 (21): 1546.

https://doi.org/10.1182/blood.V122.21.1546.1546

Published: 2013

Journal Articles

Abnormalities Of 12p Are Associated With High-Risk Acute Myeloid Leukemia: A Children’s Oncology Group Report

Betsy Hirsch, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Samir Kahwash, MD, Amy Heerema-McKenney, Richard Aplenc, MD, PhD, Lillian Sung, MD, PhD, Laura Winter, PharmD, Kathleen Glick, CCRP, Stella M. Davies, MBBS, PhD, Patti Byron, MSN, RN, Robert S. Lavey, MD, Franklin O. Smith, MD, Phoenix A. Ho, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD

Blood (2013) 122 (21): 612.

https://doi.org/10.1182/blood.V122.21.612.612

Published: 2013

Journal Articles

Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531

Alan S. Gamis, MD, MPH, Richard Aplenc, MD, PhD, Todd A. Alonzo, PhD, Lillian Sung, MD, PhD, Soheil Meshinchi, MD, PhD, Robert B. Gerbing, MA, Susana C. Raimondi, PhD, Betsy Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, CCRP, Stella M. Davies, MBBS, PhD, Patti Byron, MSN, RN, Franklin O. Smith, MD

Blood (2013) 122 (21): 355.

https://doi.org/10.1182/blood.V122.21.355.355

Published: 2013

Journal Articles

Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Children’s Oncology Group

Jessica Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Susana C Raimondi, PhD, Betsy Hirsch, PhD, Richard Aplenc, MD, Alan S. Gamis, MD, MPH, Michael R. Loken, PhD, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 491.

https://doi.org/10.1182/blood.V122.21.491.491

Published: 2013

Journal Articles

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

Jessica A. Pollard, Todd A. Alonzo, Michael Loken, Robert B. Gerbing, Phoenix A. Ho, Irwin D. Bernstein, Susana C. Raimondi, Betsy Hirsch, Janet Franklin, Roland B. Walter, Alan Gamis, Soheil Meshinchi

Blood (2012) 119 (16): 3705–3711.

https://doi.org/10.1182/blood-2011-12-398370

Published: 2012

Journal Articles

Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors

Betsy Hirsch, LeAnn Oseth, Meghan Cain, Erin Trader, Shelley Pulkrabek, Bruce Lindgren, Xianghua Luo, Mary Clay, John Miller, Dennis Confer, Daniel Weisdorf, Jeffrey McCullough

Blood (2011) 118 (9): 2602–2608.

https://doi.org/10.1182/blood-2011-04-348508

Published: 2011

Journal Articles

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Phoenix A. Ho, Rong Zeng, Todd A. Alonzo, Robert B. Gerbing, Kristen L. Miller, Jessica A. Pollard, Derek L. Stirewalt, Nyla A. Heerema, Susana C. Raimondi, Betsy Hirsch, Janet L. Franklin, Beverly Lange, Soheil Meshinchi

Blood (2010) 116 (5): 702–710.

https://doi.org/10.1182/blood-2010-02-268953

Published: 2010

Includes: Supplemental data

Journal Articles

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

Blood (2010) 115 (12): 2372–2379.

https://doi.org/10.1182/blood-2009-09-241075

Published: 2010

Journal Articles

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Jason N. Berman, MD, Robert B. Gerbing, PhD, Lillian Sung, MD, Kristen Miller, BS, Jessica A. Pollard, MD, Phoenix Ho, Derek Stirewalt, Jerald Radich, MD, Craig A. Hurwitz, MD, Nyla A. Heerema, PhD, Betsy Hirsch, MD, Susana C. Raimondi, PhD, Beverly Lange, MD, Alan S. Gamis, MD, Janet L. Franklin, MD, MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 3115.

https://doi.org/10.1182/blood.V114.22.3115.3115

Published: 2009

Journal Articles

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Phoenix A. Ho, Todd A. Alonzo, Robert B. Gerbing, Jessica Pollard, Derek L. Stirewalt, Craig Hurwitz, Nyla A. Heerema, Betsy Hirsch, Susana C. Raimondi, Beverly Lange, Janet L. Franklin, Jerald P. Radich, Soheil Meshinchi

Blood (2009) 113 (26): 6558–6566.

https://doi.org/10.1182/blood-2008-10-184747

Published: 2009

Includes: Supplemental data

Journal Articles

Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group

Jessica A Pollard, Rong Zeng, Phoenix Ho, Todd Alonzo, PhD, Robert Gerbing, Derek Stirewalt, Nyla A. Heerema, PhD, Susana C. Raimondi, PhD, Betsy Hirsch, Janet Franklin, MD, MPH, Beverly Lange, MD, Soheil Meshinchi, MD, PhD

Blood (2008) 112 (11): 143.

https://doi.org/10.1182/blood.V112.11.143.143

Published: 2008

NARROW

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO - a Report from the Children's Oncology Group

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children’s Oncology Group report

Family History Of Hematologic Malignancies and Disorders In a Population Based Study Of Myelodysplastic Syndromes (MDS)

Disease Characteristics and Prognostic Implications Of Cell Surface FLT3 Receptor (CD135) Expression In Pediatric Acute Myeloid Leukemia – A Report From Children’s Oncology Group

Differences In Community and Academic Practice Patterns For Newly Diagnosed Myelodysplastic Syndromes (MDS) Patients In Minnesota: A Population Based Study

Discordant World Health Organization (WHO) Classifications In a Population-Based Study Of Adult Myelodysplastic Syndromes (MDS)

Abnormalities Of 12p Are Associated With High-Risk Acute Myeloid Leukemia: A Children’s Oncology Group Report

Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531

Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Children’s Oncology Group

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only